LACTOLOGY FOUNDATION

Sulfasalazine (ATC A07EC01)

ATC class and general pharmacology

Sulfasalazine belongs to Anatomical Therapeutic Chemical (ATC) class A07EC01, situated within the alimentary tract and metabolism group (A), under antidiarrheals, intestinal anti-inflammatory/anti-infective agents (A07), intestinal anti-inflammatory agents (A07E), and specifically the subclass of aminosalicylic acid and similar agents (A07EC), alongside mesalazine (A07EC02), olsalazine (A07EC03), and balsalazide (A07EC04).pubchem.ncbi.nlm.nih

Chemically, sulfasalazine (salicylazosulfapyridine) is a prodrug in which 5-aminosalicylic acid (5-ASA, mesalamine) is linked to the sulfonamide antibiotic sulfapyridine via an azo bond. This molecular design confers site-specific colonic delivery: sulfasalazine is a large, poorly absorbed molecule (less than 15% of an oral dose is absorbed intact), so the bulk of the drug reaches the colon intact, where resident bacterial azoreductases cleave the azo bond, liberating sulfapyridine (systemically absorbed) and 5-ASA (acting predominantly at the local mucosal level) (StatPearls; Drugs.com).ncbi.nlm.nih+1

The precise mechanism of anti-inflammatory action remains incompletely defined, but several complementary pathways have been proposed. Sulfasalazine and its metabolites inhibit nuclear factor kappa-B (NF-κB) signalling, thereby suppressing transcription of pro-inflammatory genes including tumour necrosis factor-alpha (TNF-α); they promote caspase-8-mediated apoptosis of macrophages; they inhibit osteoclastogenesis by suppressing RANKL expression while stimulating osteoprotegerin; and they enhance adenosine-mediated anti-inflammatory signalling, which reduces leukocyte accumulation independently of NF-κB or prostaglandin pathways. Sulfasalazine and its metabolites also inhibit B-cell function and immunoglobulin (IgM/IgG) production without materially affecting T-cell activity (StatPearls; Frontiers in Pharmacology). The 5-ASA component acts locally within the bowel lumen, scavenging reactive oxygen species, inhibiting neutrophil infiltration, and preserving mucosal barrier integrity, while sulfapyridine contributes systemic anti-inflammatory and immunomodulatory activity.ncbi.nlm.nih+1

Pharmacokinetically, peak serum concentrations of sulfasalazine occur between 3 and 12 hours post-ingestion (mean approximately 6 hours), whereas sulfapyridine and 5-ASA reach peak plasma levels at approximately 10 hours, reflecting the dependency on colonic bacterial cleavage. The elimination half-life of sulfasalazine is 7.6 ± 3.4 hours; total body clearance is approximately 1 L/hour, of which renal clearance accounts for roughly 37%. Sulfapyridine undergoes hepatic acetylation with marked interindividual variability governed by acetylator phenotype.ncbi.nlm.nih

Clinically, sulfasalazine is classified as a disease-modifying anti-rheumatic drug (DMARD) and intestinal anti-inflammatory agent. Approved indications include ulcerative colitis (induction and maintenance of remission) and rheumatoid arthritis (including polyarticular-course juvenile idiopathic arthritis); off-label use extends to ankylosing spondylitis, psoriatic arthritis, and mild-to-moderate Crohn's disease (StatPearls; Drugs.com). Typical adult dosing for ulcerative colitis is 3–4 g/day in divided doses during active disease, with maintenance doses of approximately 2 g/day; rheumatoid arthritis regimens generally begin at 0.5–1 g/day, titrated upward as tolerated (Drugs.com; NCBI Bookshelf).ncbi.nlm.nih+2

Toxicological profile

Sulfasalazine exhibits low acute oral toxicity in the absence of hypersensitivity; a single oral dose of 12 g/kg was not lethal in murine models, and human survival has been documented following ingestion of considerably supratherapeutic doses (e.g., a reported suicide attempt with 25 g resulted in survival without sequelae) (Journal of Toxicology; Pfizer Medical Information). The severity of toxicity in overdose correlates with total serum sulfapyridine concentration rather than with the parent compound. Overdose manifestations typically include nausea, vomiting, abdominal pain, gastric distress, haematuria, and crystalluria; more advanced presentations may include central nervous system depression, drowsiness, and convulsions. Management is largely supportive (gastric decontamination where appropriate, urine alkalinisation, and hydration if renal function is preserved), and dialysis may facilitate removal given the low molecular weight of the drug and its metabolites (Pfizer Medical Information; Medsafe).medsafe.govt+2

Chronic and idiosyncratic toxicity is of greater clinical significance than acute overdose. Sulfasalazine shares the toxic potential of other sulfonamides, principally attributable to the sulfapyridine moiety. Common, generally reversible adverse effects include anorexia, nausea, vomiting, headache, fever, arthralgia, and skin rash, occurring in up to 20–50% of patients, predominantly within the first weeks to months of therapy (European Respiratory Society; Clinical and Experimental Rheumatology).clinexprheumatol+1

Haematological toxicity constitutes the most frequently fatal adverse effect category in long-term surveillance data, encompassing agranulocytosis, aplastic anaemia, neutropenia, pancytopenia, leucopenia, thrombocytopenia, and folate-deficiency anaemia (sulfasalazine inhibits intestinal folate absorption and metabolism). A UK fatal-toxicity surveillance review (1963–2000) attributed 42 of 68 recorded fatalities to haemopoietic causes, compared with 8 hepatobiliary, 4 cardiovascular, and 2 respiratory fatalities.publications.ersnet

Hepatotoxicity manifests as an idiosyncratic, hypersensitivity-type injury, typically presenting with fever and rash followed by jaundice within days to weeks of initiation, often accompanied by eosinophilia or atypical lymphocytosis; presentations range from mild transaminase elevation to acute hepatitis and, rarely, fulminant hepatic failure (NCBI Bookshelf/LiverTox; Clinical and Experimental Rheumatology). Renal toxicity includes crystalluria, interstitial nephritis, and membranous glomerulonephritis; adequate hydration mitigates crystalluria risk. Pulmonary toxicity, though rare, includes eosinophilic pneumonia, interstitial lung disease, pneumonitis, and pulmonary fibrosis, with a classic triad of dyspnoea, cough, and fever. Severe hypersensitivity reactions—including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalised exanthematous pustulosis—can be life-threatening and typically emerge within the first month of therapy (WebMD; Mayo Clinic). A recent pharmacovigilance analysis additionally identified acute febrile neutrophilic dermatosis, aseptic meningitis, glomerulonephritis, and hepatosplenic T-cell lymphoma as emerging safety signals. Reversible oligospermia and male infertility have also been documented, resolving upon drug discontinuation (Medsafe; Frontiers in Pharmacology). Contraindications include known hypersensitivity to sulfonamides or salicylates, porphyria, and severe hepatic or renal impairment.mayoclinic+7

Lactation pharmacology and infant exposure

Sulfasalazine and its principal active metabolite, 5-aminosalicylic acid, are transferred into human milk only in low, generally insignificant concentrations. In contrast, the secondary metabolite N-acetyl-5-ASA accumulates in breast milk at markedly higher concentrations than 5-ASA itself (reported milk concentrations of 5.0–14.9 μg/mL for N-acetyl-5-ASA versus 4–40 ng/mL for 5-ASA in one pharmacokinetic study), although the clinical significance of this metabolite for the breastfed infant has not been established through dedicated infant-outcome studies (PMC; PubMed).pubmed.ncbi.nlm.nih+1

Sulfapyridine, the sulfonamide component, is excreted into milk at concentrations equivalent to approximately 30–60% of maternal serum levels (Drugs.com/LactMed; droracle.ai). Using conventional weight-adjusted dosing calculations (based on an assumed infant milk intake of ~150 mL/kg/day), the resulting infant exposure to 5-ASA falls well below 10% of a standard paediatric therapeutic dose, generally regarded as the threshold of clinical concern for maternal medication transfer via milk.pmc.ncbi.nlm.nih+2

Because sulfapyridine is a sulfonamide, it possesses a theoretical capacity to displace bilirubin from plasma protein binding sites, raising a hypothetical risk of kernicterus in neonates, particularly those who are premature or younger than one month; empirically, however, sulfapyridine has demonstrated poor bilirubin-displacing capacity in comparative studies. A more clinically substantiated, though uncommon, risk is haemolysis in the nursing infant, especially in those with glucose-6-phosphate dehydrogenase (G6PD) deficiency; the period of greatest haemolytic risk in full-term G6PD-normal neonates has been estimated at as little as eight days after birth.pubmed.ncbi.nlm.nih+1

Gastrointestinal effects in breastfed infants have been reported in isolated cases, including bloody diarrhoea and watery diarrhoea attributed to maternal sulfasalazine or 5-ASA suppository use; in reported cases with documented outcomes, symptoms resolved upon discontinuation of either the maternal medication or breastfeeding. Because these reports are limited in number, a definitive causal relationship has not been established, though it cannot be excluded (PubMed/LactMed; Drugs.com/LactMed). A case-control follow-up study comparing infants of mothers taking mesalamine, olsalazine, or sulfasalazine (n = 121 exposed) against unexposed controls found no statistically significant difference in the frequency or nature of maternally reported adverse events over a mean follow-up period of approximately 22 months.pubmed.ncbi.nlm.nih+2

Sulfasalazine additionally inhibits maternal intestinal folate absorption and hepatic folate metabolism; sustained maternal folate depletion during lactation may reduce folate availability in breast milk in the absence of adequate supplementation (Medsafe; droracle.ai).medsafe.govt+1

Lactological safety assessment and clinical recommendations

Sulfasalazine is classified by contemporary specialist guidelines as compatible with breastfeeding for the majority of nursing mother-infant dyads. The 2020 American College of Rheumatology reproductive health guideline and the 2025 European Alliance of Associations for Rheumatology (EULAR) guidance both place sulfasalazine in the highest compatibility category for use during lactation, alongside agents such as hydroxychloroquine, colchicine, and tumour necrosis factor inhibitors. The WHO/UNICEF breastfeeding and maternal medication reference likewise lists sulfasalazine as compatible with breastfeeding, contingent on infant monitoring. National-level guidance shows some divergence: United States sources recommend general caution; Australian sources recommend use only when maternal benefit clearly outweighs infant risk, with particular caution in premature or G6PD-deficient infants; and United Kingdom sources have historically advised against breastfeeding during sulfasalazine therapy, reflecting a more conservative regulatory stance not universally shared by specialist societies.iris.who+2

Based on the convergent evidence base, the following lactological safety assessment and clinical recommendations are proposed:

• Overall risk categorisation: Low risk to the term, healthy breastfed infant when the maternal indication requires ongoing treatment; discontinuation of breastfeeding is not routinely warranted on the basis of sulfasalazine exposure alone (PubMed/LactMed; droracle.ai).pubmed.ncbi.nlm.nih+1
• High-risk infant subgroups requiring heightened caution: Premature neonates, infants younger than one month, and infants with known or suspected G6PD deficiency, in whom the risk of haemolysis and, theoretically, kernicterus is greatest. In G6PD-deficient infants, a shared decision between the treating physician and mother should weigh discontinuation of either breastfeeding or the maternal medication (WHO/IRIS; Drugs.com/LactMed).iris.who+1
• Infant clinical monitoring: Breastfed infants of mothers on sulfasalazine should be observed for bloody or watery diarrhoea, jaundice, pallor, or other signs suggestive of haemolysis, particularly during the first weeks of exposure (PubMed/LactMed; droracle.ai).pubmed.ncbi.nlm.nih+1
• Maternal folate supplementation: Continued daily folic acid supplementation (typically 1–5 mg/day depending on indication and local protocol) is recommended throughout sulfasalazine therapy during lactation to offset the drug's antifolate effect and preserve maternal and milk folate status.droracle
• Preference among 5-ASA derivatives: Where clinically feasible and disease control permits, non-sulfonamide 5-ASA derivatives (e.g., mesalazine, ATC A07EC02) may be preferred over sulfasalazine during lactation, since they avoid the sulfapyridine-related haemolytic and bilirubin-displacement concerns, although data on their own infant safety remain similarly limited.pubmed.ncbi.nlm.nih
• Maternal monitoring during lactation: Periodic maternal full blood count, liver function tests, and renal function tests should continue according to standard sulfasalazine surveillance protocols (e.g., British Society for Rheumatology intervals) irrespective of lactation status, since maternal haematological or hepatic toxicity could indirectly compromise infant care.pmc.ncbi.nlm.nih
• Dose considerations: No specific lactation-adjusted dosing has been validated; the maternal dose required for adequate disease control (commonly up to 2 g/day for maintenance) should be used, since underdosing does not reduce infant exposure meaningfully but may compromise maternal disease control.droracle

In summary, the weight of pharmacokinetic and clinical-outcome evidence supports continuation of breastfeeding during maternal sulfasalazine therapy in most circumstances, provided that structured infant monitoring is implemented and heightened vigilance is applied in premature, very young, or G6PD-deficient infants.